Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Effects of Rifampicin or Itraconazole on Larotinib in Healthy Subjects
NCT05057949Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2021
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of larotinib in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Infinity. Started Nov 2021; status: completed.
02
Drugs
larotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05057949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05057949.